Molecular Oncology
Volume 1, Issue 1 , Pages 97-119 , June 2007

Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia

  • Julio E. Celis

      Affiliations

    • Danish Centre for Translational Breast Cancer Research (DCTB), Strandboulevarden 49, DK-2100 Copenhagen, Denmark
    • Department of Proteomics in Cancer, Institute of Cancer Biology, Danish Cancer Society, Strandboulevarden 49, DK-2100 Copenhagen, Denmark
    • Corresponding Author InformationCorresponding author. Department of Proteomics in Cancer, Institute of Cancer Biology, Danish Cancer Society, Strandboulevarden 49, DK-2100 Copenhagen, Denmark. Tel.: +45 35257363; Fax: +45 35257375.
    • ,
  • José M.A. Moreira

      Affiliations

    • Danish Centre for Translational Breast Cancer Research (DCTB), Strandboulevarden 49, DK-2100 Copenhagen, Denmark
    • Department of Proteomics in Cancer, Institute of Cancer Biology, Danish Cancer Society, Strandboulevarden 49, DK-2100 Copenhagen, Denmark
    • ,
  • Irina Gromova

      Affiliations

    • Danish Centre for Translational Breast Cancer Research (DCTB), Strandboulevarden 49, DK-2100 Copenhagen, Denmark
    • Department of Proteomics in Cancer, Institute of Cancer Biology, Danish Cancer Society, Strandboulevarden 49, DK-2100 Copenhagen, Denmark
    • ,
  • Teresa Cabezón

      Affiliations

    • Danish Centre for Translational Breast Cancer Research (DCTB), Strandboulevarden 49, DK-2100 Copenhagen, Denmark
    • Department of Proteomics in Cancer, Institute of Cancer Biology, Danish Cancer Society, Strandboulevarden 49, DK-2100 Copenhagen, Denmark
    • ,
  • Pavel Gromov

      Affiliations

    • Danish Centre for Translational Breast Cancer Research (DCTB), Strandboulevarden 49, DK-2100 Copenhagen, Denmark
    • Department of Proteomics in Cancer, Institute of Cancer Biology, Danish Cancer Society, Strandboulevarden 49, DK-2100 Copenhagen, Denmark
    • ,
  • Tao Shen

      Affiliations

    • Danish Centre for Translational Breast Cancer Research (DCTB), Strandboulevarden 49, DK-2100 Copenhagen, Denmark
    • Department of Proteomics in Cancer, Institute of Cancer Biology, Danish Cancer Society, Strandboulevarden 49, DK-2100 Copenhagen, Denmark
    • T. Shen is a visiting scientist from the Institute of Basic Medicine, The First People's Hospital of Yunnan Province, PR China.
    • ,
  • Vera Timmermans

      Affiliations

    • Danish Centre for Translational Breast Cancer Research (DCTB), Strandboulevarden 49, DK-2100 Copenhagen, Denmark
    • Department of Pathology, the Centre of Diagnostic Investigations, Rigshospitalet, Copenhagen, Denmark
    • ,
  • Fritz Rank

      Affiliations

    • Danish Centre for Translational Breast Cancer Research (DCTB), Strandboulevarden 49, DK-2100 Copenhagen, Denmark
    • Department of Pathology, the Centre of Diagnostic Investigations, Rigshospitalet, Copenhagen, Denmark

Received 25 January 2007 ,Revised 22 February 2007 ,Accepted 22 February 2007.

References 

  1. Adriance MC, Inman JL, Petersen OW, Bissell MJ. Myoepithelial cells: good fences make good neighbors. Breast Cancer Res. 2005;7:190–197
  2. Agnantis NJ, Mahera H, Maounis N, Spandidos DA. Immunohistochemical study of ras and myc oncoproteins in apocrine breast lesions with and without papillomatosis. Eur. J. Gynaecol. Oncol. 1992;13:309–315
  3. Aitken A. 14-3-3 and its possible role in co-ordinating multiple signalling pathways. Trends Cell Biol. 1996;6:341–347
  4. Allred DC, Mohsin SK. Biological features of human premalignant breast disease. In:  Harris R editors. Diseases of the Breast. Philadelphia: Lippincott Williams & Wilkins; 2000;
  5. Allred DC, Mohsin SK, Fuqua SA. Histological and biological evolution of human premalignant breast disease. Endocri. Relat. Cancer. 2001;8:47–61
  6. Angeli A, Bradlow HL, Bodian CA, Chasalow FI, Dogliotti L, Haagensen DE. Criteria for classifying breast cyst fluids. Ann. N.Y. Acad. Sci. 1990;586:49–52
  7. Arai K, Teratani T, Kuruto-Niwa R, Yamada T, Nozawa R. S100A9 expression in invasive ductal carcinoma of the breast: S100A9 expression in adenocarcinoma is closely associated with poor tumour differentiation. Eur. J. Cancer. 2004;40:1179–1187
  8. Bankfalvi A, Ludwig A, De-Hesselle B, Buerger H, Buchwalow IB, Boecker W. Different proliferative activity of the glandular and myoepithelial lineages in benign proliferative and early malignant breast diseases. Mod. Pathol. 2004;17:1051–1061
  9. Barbareschi M, Pecciarini L, Cangi MG, Macri E, Rizzo A, Viale G, et al. p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am. J. Surg. Pathol. 2001;25:1054–1060
  10. Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature. 2006;444:633–637
  11. Berman JJ, Albores-Saavedra J, Bostwick D, Delellis R, Eble J, Hamilton SR, et al. Precancer: a conceptual working definition – results of a Consensus Conference. Cancer Detect. Prev. 2006;30:387–394
  12. Bocker W, Moll R, Poremba C, Holland R, Van Diest PJ, Dervan P, et al. Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept. Lab. Invest. 2002;82:737–746
  13. Bolli M, Kocher T, Adamina M, Guller U, Dalquen P, Haas P, et al. Tissue microarray evaluation of melanoma antigen E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma. Ann. Surg. 2002;236:785–793
  14. Bruzzi P, Dogliotti L, Naldoni C, Bucchi L, Costantini M, Cicognani A, et al. Cohort study of association of risk of breast cancer with cyst type in women with gross cystic disease of the breast. BMJ. 1997;314:925–928
  15. Carlsson H, Petersson S, Enerback C. Cluster analysis of S100 gene expression and genes correlating to psoriasin (S100A7) expression at different stages of breast cancer development. Int. J. Oncol. 2005;27:1473–1481
  16. Carter DJ, Rosen PP. Atypical apocrine metaplasia in sclerosing lesions of the breast: a study of 51 patients. Mod. Pathol. 1991;4:1–5
  17. Celis JE, Ostergaard M, Basse B, Celis A, Lauridsen JB, Ratz GP, et al. Loss of adipocyte-type fatty acid binding protein and other protein biomarkers is associated with progression of human bladder transitional cell carcinomas. Cancer Res. 1996;56:4782–4790
  18. Celis JE, Celis P, Ostergaard M, Basse B, Lauridsen JB, Ratz G, et al. Proteomics and immunohistochemistry define some of the steps involved in the squamous differentiation of the bladder transitional epithelium: a novel strategy for identifying metaplastic lesions. Cancer Res. 1999;59:3003–3009
  19. Celis A, Rasmussen HH, Celis P, Basse B, Lauridsen JB, Ratz G, et al. Short-term culturing of low-grade superficial bladder transitional cell carcinomas leads to changes in the expression levels of several proteins involved in key cellular activities. Electrophoresis. 1999;20:355–361
  20. Celis JE, Gromov P, Gromova I, Moreira JM, Cabezon T, Ambartsumian N, et al. Integrating proteomic and functional genomic technologies in discovery-driven translational breast cancer research. Mol. Cell. Proteomics. 2003;2:369–377
  21. Celis JE, Gromov P, Cabezon T, Moreira JM, Ambartsumian N, Sandelin K, et al. Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery. Mol. Cell. Proteomics. 2004;3:327–344
  22. Celis JE, Moreira JM, Gromova I, Cabezon T, Ralfkiaer U, Guldberg P, et al. Towards discovery-driven translational research in breast cancer. FEBS J. 2005;272:2–15
  23. Celis JE, Moreira JM, Cabezon T, Gromov P, Friis E, Rank F, et al. Identification of extracellular and intracellular signaling components of the mammary adipose tissue and its interstitial fluid in high risk breast cancer patients: toward dissecting the molecular circuitry of epithelial-adipocyte stromal cell interactions. Mol. Cell. Proteomics. 2005;4:492–522
  24. Celis JE, Gromov P, Moreira JM, Cabezon T, Friis E, Vejborg IM, et al. Apocrine cysts of the breast: biomarkers, origin, enlargement, and relation with cancer phenotype. Mol. Cell Proteomics. 2006;5:462–483
  25. Celis JE, Gromova I, Gromov P, Moreira JM, Cabezon T, Friis E, et al. Molecular pathology of breast apocrine carcinomas: a protein expression signature specific for benign apocrine metaplasia. FEBS Lett. 2006;580:2935–2944
  26. Celis JE, Trentemølle S, Gromov P. Gel-based proteomics: high-resolution two-dimensional gel electrophoresis of proteins. isoelectric focusing (IEF) and nonequilibrium pH gradient electrophoresis (NEPHGE). In:  Celis JE,  Carter N,  Hunter T,  Simons K,  Small JV,  Shotton D editor. A Cell Biology. Laboratory Handbook. third ed.. San Diego: Academic Press; 2006;p. 165–1744 V
  27. Celis JE, Moreira JMA, Gromov P. Determination of antibody specificity by Western blotting. In:  Celis JE,  Carter N,  Hunter T,  Simons K,  Small JV,  Shotton D editor. A Cell Biology. Laboratory Handbook. third ed.. San Diego: Academic Press; 2006;p. 527–5324 V
  28. Chan K, Morris GJ. Chemoprevention of breast cancer for women at high risk. Semin. Oncol. 2006;33:642–646
  29. Clahsen PC, van de Velde CJ, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, et al. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J. Clin. Oncol. 1998;16:470–479
  30. Collado M, Gil J, Efeyan A, Guerra C, Schuhmache AJ, Barradas M, et al. Tumour biology: senescence in premalignant tumours. Nature. 2005;436:642
  31. Collins I, Workman P. New approaches to molecular cancer therapeutics. Nat. Chem. Biol. 2006;2:689–700
  32. Costa A, Bonanni B, Manetti L, Guerrieri Gonzaga A, Torrisi R, Decensi A. Prevention of breast cancer: focus on chemoprevention. Recent Results. Cancer Res. 1998;152:11–21
  33. Courtois-Cox S, Genther Williams SM, Reczek EE, Johnson BW, McGillicuddy LT, Johannessen CM, et al. A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell. 2006;10:459–472
  34. Cyrlak D, Carpenter PM. Breast imaging case of the day. Fat necrosis of the breast. Radiographics. 1999;19:S80–S83
  35. Dabbs DJ, Carter G, Fudge M, Peng Y, Swalsky P, Finkelstein S. Molecular alterations in columnar cell lesions of the breast. Mod. Pathol. 2006;19:344–349
  36. Dawson PJ, Wolman SR, Tait L, Heppner GH, Miller FR. MCF10AT: a model for the evolution of cancer from proliferative breast disease. Am. J. Pathol. 1996;148:313–319
  37. Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C, et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature. 2006;444:638–642
  38. Durham JR, Fechner RE. The histologic spectrum of apocrine lesions of the breast. Am. J. Clin. Pathol. 2000;113(5 Suppl. 1):S3–S18
  39. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403–410
  40. Endoh Y, Tamura G, Kato N, Motoyama T. Apocrine adenosis of the breast: clonal evidence of neoplasia. Histopathology. 2001;38:221–224
  41. Enerback C, Porter DA, Seth P, Sgroi D, Gaudet J, Weremowicz S, et al. Psoriasin expression in mammary epithelial cells in vitro and in vivo. Cancer Res. 2002;62:43–47
  42. Fridriksdottir AJ, Villadsen R, Gudjonsson T, Petersen OW. Maintenance of cell type diversification in the human breast. J. Mammary Gland Biol. Neoplasia. 2005;10:61–74
  43. Gatalica Z. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ. Pathol. Res. Pract. 1997;193:753–758
  44. Gebhardt C, Nemeth J, Angel P, Hess J. S100A8 and S100A9 in inflammation and cancer. Biochem. Pharmacol. 2006;72:1622–1631
  45. Gordon LA, Mulligan KT, Maxwell-Jones H, Adams M, Walker RA, Jones JL. Breast cell invasive potential relates to the myoepithelial phenotype. Int. J. Cancer. 2003;106:8–16
  46. Gromova I, Celis JE. Protein detection in gels by silver staining: a procedure compatible with mass-spectrometry. In:  Celis JE,  Carter N,  Hunter T,  Shotton D,  Simons K,  Small JV editor. Cell Biology. A Laboratory Handbook. vol. 4:San Diego: Academic Press; 2006;p. 219–223
  47. Gudjonsson T, Ronnov-Jessen L, Villadsen R, Rank F, Bissell MJ, Petersen OW. Normal and tumor-derived myoepithelial cells differ in their ability to interact with luminal breast epithelial cells for polarity and basement membrane deposition. J. Cell. Sci. 2002;115:39–50
  48. Gudjonsson T, Ronnov-Jessen L, Villadsen R, Bissell MJ, Petersen OW. To create the correct microenvironment: three-dimensional heterotypic collagen assays for human breast epithelial morphogenesis and neoplasia. Methods. 2003;30:247–255
  49. Gudjonsson T, Adriance MC, Sternlicht MD, Petersen OW, Bissell MJ. Myoepithelial cells: their origin and function in breast morphogenesis and neoplasia. J. Mammary Gland Biol. Neoplasia. 2005;10:261–272
  50. Guinebretière JM, Menet E, Tardivon A, Cherel P, Vanel D. Normal and pathological breast, the histological basis. Eur. J. Radiol. 2005;54:6–14
  51. Haagensen CD. In: Diseases of the Breast. third ed.. Philadelphia: W.B. Saunders; 1986;p. 250–266
  52. Haagensen DE. Is cystic disease related to breast cancer?. Am. J. Surg. Pathol. 1991;15:687–694
  53. Herceg, Z., Hainaut, P. Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosis. Mol. Oncol., doi:10.1016/j.molonc.2007.01.004.
  54. Jih DM, Lyle S, Elenitsas R, Elder DE, Cotsarelis G. Cytokeratin 15 expression in trichoepitheliomas and a subset of basal cell carcinomas suggests they originate from hair follicle stem cells. J. Cutan. Pathol. 1999;26:113–118
  55. Jones C, Damiani S, Wells D, Chaggar R, Lakhani SR, Eusebi V. Molecular cytogenetic comparison of apocrine hyperplasia and apocrine carcinoma of the breast. Am. J. Pathol. 2001;158:207–214
  56. Kenny, P.A., Lee, G.Y., Myers, C.A., Neve, R.M., Semeiks, J.R., Spellman, P.T., Lorenz, K., Lee, E.H., Barcellos-Hof, M.H., Petersen, O.W., Gray, J.W. and Bissel, M.J. The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol. Oncol., doi:10.1016/j.molonc.2007.02.004.
  57. Kerlikowske K, Grady D, Rubin SM, Sandrock C, Ernster VL. Efficacy of screening mammography. A meta-analysis. JAMA. 1995;273:149–154
  58. Krishnamurthy S, Sneige N. Molecular and biologic markers of premalignant lesions of human breast. Adv. Anat. Pathol. 2002;9:185–197
  59. Krop I, Marz A, Carlsson H, Li X, Bloushtain-Qimron N, Hu M, et al. A putative role for psoriasin in breast tumor progression. Cancer Res. 2005;65:11326–11334
  60. Lacroix M. Significance, detection and markers of disseminated breast cancer cells. Endocr. Relat. Cancer. 2006;13:1033–1067
  61. Lai LC, Kadory S, Siraj AK, Lennard TW. Oncostatin M, interleukin 2, interleukin 6 and interleukin 8 in breast cyst fluid. Int. J. Cancer. 1994;59:369–372
  62. Lai LC, Siraj AK, Erbas H, Lennard TW. Transforming growth factor alpha, beta 1 and beta 2 in breast cyst fluid. Anticancer Res. 1994;14:2805–2809
  63. Landry C, Brasseur F, Spagnoli GC, Marbaix E, Boon T, Coulie P, et al. Monoclonal antibody 57B stains tumor tissues that express gene MAGE-A4. Int. J. Cancer. 2000;86:835–841
  64. Leffers H, Madsen P, Rasmussen HH, Honore B, Andersen AH, Walbum E, et al. Molecular cloning and expression of the transformation sensitive epithelial marker stratifin. A member of a protein family that has been involved in the protein kinase C signalling pathway. J. Mol. Biol. 1993;231:982–998
  65. Lerwill MF. Current practical applications of diagnostic immunohistochemistry in breast pathology. Am. J. Surg. Pathol. 2004;28:1076–1091
  66. Liefers GJ, Tollenaar RA. Cancer genetics and their application to individualised medicine. Eur. J. Cancer. 2002;38:872–879
  67. Madsen P, Rasmussen HH, Leffers H, Honore B, Dejgaard K, Olsen E, et al Molecular cloning, occurrence, and expression of a novel partially secreted protein “psoriasin” that is highly up-regulated in psoriatic skin. J. Invest. Dermatol. 1991;97:701–712
  68. Mazoujian G, Pinkus GS, Davis S, Haagensen DE. Immunohistochemistry of a gross cystic disease fluid protein (GCDFP-15) of the breast. A marker of apocrine epithelium and breast carcinomas with apocrine features. Am. J. Pathol. 1983;110:105–112
  69. McCann A, Johnston PA, Dervan PA, Gullick WJ, Carney DN. c-erB-2 oncoprotein expression in malignant and nonmalignant breast tissue. Ir. J. Med. Sci. 1989;158:137–140
  70. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature. 1999;398:708–713
  71. Moll R. Cytokeratins as markers of differentiation in the diagnosis of epithelial tumors. Subcell. Biochem. 1998;31:205–262
  72. Moreira JM, Ohlsson G, Rank FE, Celis JE. Down-regulation of the tumor suppressor protein 14-3-3sigma is a sporadic event in cancer of the breast. Mol. Cell. Proteomics. 2005;4:555–569
  73. Moriya T, Sakamoto K, Sasano H, Kawanaka M, Sonoo H, Manabe T, et al. Immunohistochemical analysis of Ki-67, p53, p21, and p27 in benign and malignant apocrine lesions of the breast: its correlation to histologic findings in 43 cases. Mod. Pathol. 2000;13:13–18
  74. Moriya T, Kasajima A, Ishida K, Kariya Y, Akahira J, Endoh M, et al. New trends of immunohistochemistry for making differential diagnosis of breast lesions. Med. Mol. Morphol. 2006;39:8–13
  75. Nagaraja GM, Othman M, Fox BP, Alsaber R, Pellegrino CM, Zeng Y, et al. Gene expression signatures and biomarkers of noninvasive and invasive breast cancer cells: comprehensive profiles by representational difference analysis, microarrays and proteomics. Oncogene. 2006;25:2328–2338
  76. Ness JC, Sedghinasab M, Moe RE, Tapper D. Identification of multiple proliferative growth factors in breast cyst fluid. Am. J. Surg. 1993;166:237–243
  77. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. Aug 15 2004;10(16):5367–5374
  78. O'Farrell PH. High resolution two-dimensional electrophoresis of proteins. J. Biol. Chem. 1975;250:4007–4021
  79. O'Malley FP, Bane AL. The spectrum of apocrine lesions of the breast. Adv. Anat. Pathol. 2004;11:1–9
  80. Ohyama M, Vogel JC, Amagai M. Gene ontology analysis of human hair follicle bulge molecular signature. J. Dermatol. Sci. 2007;45:147–150
  81. Olsen O, Gotzsche PC. Cochrane review on screening for breast cancer with mammography. Lancet. 2001;358:1340–1342
  82. Ostergaard M, Wolf H, Orntoft TF, Celis JE. Psoriasin (S100A7): a putative urinary marker for the follow-up of patients with bladder squamous cell carcinomas. Electrophoresis. 1999;20:349–354
  83. Page DL, Simpson JF. What is apocrine adenosis, anyway?. Histopathology. 2001;39:433–434
  84. Papamichalis G, Francia K, Karachaliou FE, Anastasiades OT, Spandidos DA. Expression of the c-myc oncoprotein in human metaplastic epithelial cells of fibrocystic disease. Anticancer Res. 1988;8:1217–1222
  85. Pathology Reporting Of Breast Cancer, 2005. NHS Breast Screening Programme Publication no. 58.
  86. Pechoux C, Gudjonsson T, Ronnov-Jessen L, Bissell MJ, Petersen OW. Human mammary luminal epithelial cells contain progenitors to myoepithelial cells. Dev. Biol. 1999;206:88–99
  87. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–752
  88. Pinder SE, Reis-Filho JS. Non operative breast pathology: columnar cell lesions. J. Clin. Pathol. 2006;(Epub ahead of print)
  89. Pinder SE, Wencyk P, Sibbering DM, Bell JA, Elston CW, Nicholson R, et al. Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br. J. Cancer. 1995;71:146–149
  90. Polyak K, Hu M. Do myoepithelial cells hold the key for breast tumor progression?. J. Mammary Gland Biol. Neoplasia. 2005;10:231–247
  91. Quidville V, Segond N, Lausson S, Frenkian M, Cohen R, Jullienne A. 15-Hydroxyprostaglandin-dehydrogenase is involved in anti-proliferative effect of non-steroidal anti-inflammatory drugs COX-1 inhibitors on a human medullary thyroid carcinoma cell line. Prostaglandins Other Lipid Mediat. 2006;81:14–30
  92. Rabinovitz I, Mercurio AM. The integrin alpha6beta4 functions in carcinoma cell migration on laminin-1 by mediating the formation and stabilization of actin-containing motility structures. J. Cell Biol. 1997;139:1873–1884
  93. Reed MJ, Coldham NG, Patel SR, Ghilchik MW, James VH. Interleukin-1 and interleukin-6 in breast cyst fluid: their role in regulating aromatase activity in breast cancer cells. J. Endocrinol. 1992;132:R5–R8
  94. Rimoldi D, Salvi S, Schultz-Thater E, Spagnoli GC, Cerottini JC. Anti-MAGE-3 antibody 57B and anti-MAGE-1 antibody 6C1 can be used to study different proteins of the MAGE-A family. Int. J. Cancer. 2000;86:749–751
  95. Rohan TE, Li SQ, Hartwick R, Kandel RA. p53 Alterations and protein accumulation in benign breast tissue and breast cancer risk: a cohort study. Cancer Epidemiol. Biomarkers Prev. 2006;15:1316–1323
  96. Rosen PP. Rosen's Breast Pathology Book. Lippincott-Raven; 1997;pp. 123–142
  97. Schnitt SJ, Vincent-Salomon A. Columnar cell lesions of the breast. Adv. Anat. Pathol. 2003;10:113–124
  98. Seidman JD, Ashton M, Lefkowitz M. Atypical apocrine adenosis of the breast: a clinicopathologic study of 37 patients with 8.7-year follow-up. Cancer. 1996;77:2529–2537
  99. Selim AG, Ryan A, El-Ayat GA, Wells CA. Loss of heterozygosity and allelic imbalance in apocrine adenosis of the breast. Cancer Detect. Prev. 2001;25:262–267
  100. Selim AG, El-Ayat G, Naase M, Wells CA. C-myc oncoprotein expression and gene amplification in apocrine metaplasia and apocrine change within sclerosing adenosis of the breast. Breast. 2002;11:466–472
  101. Selim AG, El-Ayat G, Wells CA. Expression of c-erbB2, p53, Bcl-2, Bax, c-myc and Ki-67 in apocrine metaplasia and apocrine change within sclerosing adenosis of the breast. Virchows Arch. 2002;441:449–455
  102. Selim AG, Ryan A, El-Ayat G, Wells CA. Loss of heterozygosity and allelic imbalance in apocrine metaplasia of the breast: microdissection microsatellite analysis. J. Pathol. 2002;196:287–291
  103. Shevchenko A, Wilm M, Vorm O, Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 1996;68:850–858
  104. Simpson JF, Page DL. Apocrine adenosis – mimic of mammary carcinoma. Surg. Pathol. 1990;3:289–299
  105. Simpson PT, Gale T, Reis-Filho JS, Jones C, Parry S, Steele D, et al. Distribution and significance of 14-3-3sigma, a novel myoepithelial marker, in normal, benign, and malignant breast tissue. J. Pathol. 2004;202:274–285
  106. Simpson PT, Gale T, Reis-Filho JS, Jones C, Parry S, Sloane JP, et al. Columnar cell lesions of the breast: the missing link in breast cancer progression? A morphological and molecular analysis. Am. J. Surg. Pathol. 2005;29:734–746
  107. Skliris GP, Lewis A, Emberley E, Peng B, Weebadda WK, Kemp A, et al. Estrogen receptor-beta regulates psoriasin (S100A7) in human breast cancer. Breast Cancer Res. Treat. 2006;(Epub ahead of print)
  108. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U.S.A. 2001;98:10869–10874
  109. Stingl J, Eaves CJ, Kuusk U, Emerman JT. Phenotypic and functional characterization in vitro of a multipotent epithelial cell present in the normal adult human breast. Differentiation. 1998;63:201–213
  110. Stingl J, Eaves CJ, Zandieh I, Emerman JT. Characterization of bipotent mammary epithelial progenitor cells in normal adult human breast tissue. Breast Cancer Res. Treat. 2001;67:93–109
  111. Stoll BA. Premalignant breast lesions: role for biological markers in predicting progression to cancer. Eur. J. Cancer. 1999;35:693–697
  112. Tapper D, Gajdusek C, Moe R, Ness J. Identification of a unique biological tumor marker in human breast cyst fluid and breast cancer tissue. Am. J. Surg. 1990;159:473–478
  113. Tavassoli FA, Norris HJ. Intraductal apocrine carcinoma: a clinicopathologic study of 37 cases. Mod. Pathol. 1994;7:813–818
  114. Tavassoli FA, Purcell CA, Man YG. Down regulation of bcl2, ER, PR associated with AR expression is triggered by apocrine differentiation of mammary epithelium. Mod. Pathol. 1996;9:25A
  115. Triggle DJ. Drug discovery and delivery in the 21st century. Med. Princ. Pract. 2007;16:1–14
  116. Tse GM, Tan PH, Chaiwun B, Putti TC, Lui PC, Tsang AK, et al. p63 is useful in the diagnosis of mammary metaplastic carcinomas. Pathology. 2006;38:16–20
  117. van Diest PJ, van der Wall E, Baak JP. Prognostic value of proliferation in invasive breast cancer: a review. J. Clin. Pathol. 2004;57:675–681
  118. Viacava P, Naccarato AG, Bevilacqua G. Spectrum of GCDFP-15 expression in human fetal and adult normal tissues. Virchows Arch. 1998;432:255–260
  119. Villadsen, R., Fridriksdottir, A.J., Rønnov-Jessen, L., Gudjonsson, T., Rank F., LaBarge M.A., Bissel, M.J., Petersen O.W., 2007. Evidence for a stem cell hierarchy in the adult human breast. J. Cell Sci. 177, 87–101.
  120. Washington C, Dalbegue F, Abreo F, Taubenberger JK, Lichy JH. Loss of heterozygosity in fibrocystic change of the breast: genetic relationship between benign proliferative lesions and associated carcinomas. Am. J. Pathol. 2000;157:323–329
  121. Weidner N, Moore DH, Vartanian R. Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel “paraffin”-reactive MIB1 antibody. Hum. Pathol. 1994;25:337–342
  122. Wellings SR, Alpers CE. Apocrine cystic metaplasia: subgross pathology and prevalence in cancer-associated versus random autopsy breasts. Hum. Pathol. 1987;18:381–386
  123. Wellings SR, Jensen HM, Marcum RG. An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J. Natl. Cancer Inst. 1975;55:231–273
  124. Wells CA, McGregor IL, Makunura CN, Yeomans P, Davies JD. Apocrine adenosis: a precursor of aggressive breast cancer?. J. Clin. Pathol. 1995;48:737–742
  125. Wolf I, O'Kelly J, Rubinek T, Tong M, Nguyen A, Lin BT, et al. 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res. 2006;66:7818–7823
  126. Zagorianakou P, Zagorianakou N, Stefanou D, Makrydimas G, Agnantis NJ. The enigmatic nature of apocrine breast lesions. Virchows Arch. 2006;448:525–531
  127. Zhang RR, Man YG, Vang R, Saenger JS, Barner R, Wheeler DT, et al. A subset of morphologically distinct mammary myoepithelial cells lacks corresponding immunophenotypic markers. Breast Cancer Res. 2003;5:151–156

☆ This article is dedicated to the memory of Dorrit Lützhøft, a wonderful and inspiring colleague that recently succumbed to breast cancer.

PII: S1574-7891(07)00008-7

doi: 10.1016/j.molonc.2007.02.005

Molecular Oncology
Volume 1, Issue 1 , Pages 97-119 , June 2007

Article Tools

* Image Usage & Resolution